methyl 8-aminooctanoate hydrochloride | 77420-98-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl 8-aminooctanoate hydrochloride
• 英文别名: 8-methoxy-8-oxooctan-1-aminium chloride；8-aminooctanoic acid methyl ester hydrochloride；methyl 8-aminooctanoate;hydrochloride
• CAS: 77420-98-5
• 化学式: C₉H₁₉NO₂*ClH
• mdl: MFCD22375357
• 分子量: 209.716
• InChiKey: DNMCSEZPFDMEHC-UHFFFAOYSA-N

物化性质

• 熔点：
  102-104 °C ()

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  52.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 8-aminooctanoate hydrochloride 在 palladium on activated charcoal lithium hydroxide 、 TEA 、 氢气 、 双(2-氧代-3-恶唑烷基)次磷酰氯 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 10.0h， 生成 N-hydroxy-8-(4-dimethylaminobenzoyl)-aminooctanamide
  参考文献：
  名称：

  Amide Analogues of Trichostatin A as Inhibitors of Histone Deacetylase and Inducers of Terminal Cell Differentiation

  摘要：

  Inhibitors of histone deacetylase (HD) bear great potential as new drugs due to their ability to modulate transcription and to induce apoptosis or differentiation in cancer cells. We have described previously analogues of the complex natural HD inhibitors trapoxin B and trichostatin A with activities in the submicromolar range. Here we report structure-activity relationship analyses of further analogues of trichostatin A with respect to in vitro inhibition of maize HD-2 and their ability to induce terminal cell differentiation in Friend leukemic cells. This is the first report that shows the correlation between HD inhibitory activity and action on cancer cells on a larger series of similar compounds. Only the compounds that inhibit HD induce differentiation and/or exert antiproliferative activities in cell culture. Our studies support the use of in vitro systems as screening tools and provide structure-activity relationships that merit further investigation of this interesting target.

  DOI：

  10.1021/jm991091h
• 作为产物：
  描述：

  8-氨基辛酸 在 氯化亚砜 作用下， 以 甲醇 为溶剂， 生成 methyl 8-aminooctanoate hydrochloride
  参考文献：
  名称：

  Enkephalinase inhibitors

  摘要：

  巯基烷酰和酰基巯基烷酰化合物的化学式为##STR1##，其中n是从一到十五的整数，具有脑内啡酶抑制活性，并可用作镇痛剂。

  公开号：

  US04722810A1

文献信息

• HSP90 Inhibitors Containing a Zinc Binding Moiety
  申请人：Qian Changgeng

  公开号：US20080234297A1

  公开（公告）日：2008-09-25

  The present invention relates to HSP90 inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The said derivatives may further act as HDAC inhibitors.

  本发明涉及HSP90抑制剂及其在治疗癌症等细胞增殖性疾病中的应用。所述衍生物还可能作为HDAC抑制剂。
• [EN] THIENOPYRROLE COMPOUNDS AND USES THEREOF AS INHIBITORS OF OPLOPHORUS-DERIVED LUCIFERASES<br/>[FR] COMPOSÉS DE THIÉNOPYRROLE ET LEURS UTILISATIONS À TITRE D'INHIBITEURS DE LUCIFÉRASES DÉRIVÉES D'OPLOPHORUS
  申请人：PROMEGA CORP

  公开号：WO2016210294A1

  公开（公告）日：2016-12-29

  Thienopyrrole compounds that may inhibit Oplophorus -derived luciferases are disclosed, as well as compositions and kits comprising the thienopyrrole compounds, and methods of using the thienopyrrole compounds.

  披露了可能抑制Oplophorus衍生的荧光素酶的噻吩并吡咯化合物，以及包含这些噻吩并吡咯化合物的组合物和试剂盒，以及使用这些噻吩并吡咯化合物的方法。
• Development and In Vitro and In Vivo Evaluation of Microspheres Containing Sodium N-[8-(2-hydroxybenzoyl)amino]caprylate for the Oral Delivery of Berberine Hydrochloride
  作者：Ying Li、Chunyan Zhu

  DOI：10.3390/molecules25081957

  日期：——

  Microspheres containing absorption enhancer (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate, SNAC) were developed to enhance the oral bioavailability of berberine hydrochloride (BER) with poor intestinal membrane permeability. Microspheres were prepared and characterized by particle size measurements, scanning electron microscopy, differential scanning calorimetry, BER payload and release, Caco-2 cell monolayer transport, and rat pharmacokinetics. The microspheres were spherical and had uniform size, high encapsulation efficiency and high loading capacity. In vitro release studies showed that BER-loaded microspheres had good sustained release characteristics. The Caco-2 cell monolayer transport study proved that SNAC could significantly enhance permeability of BER 2–3-fold. Pharmacokinetic studies demonstrated a 9.87-fold increase in area under the curve (AUC) of BER mixed with SNAC and a 14.14-fold increase in AUC of microspheres compared with BER alone. These findings indicate that SNAC is a promising absorption enhancer for oral delivery of BER in the form of both solution and microspheres.

  含有吸收增强剂（钠N-[8-(2-羟基苯甲酰)氨基]辛酸盐，SNAC）的微球被开发出来，以提高肠道膜渗透性较差的盐酸小檗碱（BER）的口服生物利用度。通过粒径测量、扫描电子显微镜、差示扫描量热法、BER载药量和释放、Caco-2细胞单层转运以及大鼠药代动力学对微球进行制备和表征。这些微球呈球形，具有均匀的尺寸、高封装效率和高的载药量。体外释放研究表明，载有BER的微球具有良好的持续释放特性。Caco-2细胞单层转运研究表明，SNAC可以显著提高BER的渗透性2-3倍。药代动力学研究显示，与单独使用BER相比，BER与SNAC混合后的曲线下面积（AUC）增加了9.87倍，微球形式的AUC增加了14.14倍。这些发现表明，SNAC是一种有前途的吸收增强剂，可以用于BER溶液和微球形式的口服给药。
• [EN] HETEROCYCLICALKYL DERIVATIVE COMPOUNDS AS SELECTIVE HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME<br/>[FR] COMPOSÉS DÉRIVÉS D'ALKYLE HÉTÉROCYCLIQUES À UTILISER EN TANT QU'INHIBITEURS DE L'HISTONE DÉSACÉTYLASE ET COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT
  申请人：CHONG KUN DANG PHARMACEUTICAL CORP

  公开号：WO2016190630A1

  公开（公告）日：2016-12-01

  The present invention relates to novel heterocyclicalkyl derivatives having histone deacetylase (HDAC) inhibitory activity, optical isomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel heterocyclicalkyl derivatives. The novel heterocyclicalkyl derivatives according to the present invention are selective histone deacetylase (HDAC) inhibitors, and may be effectively used for the treatment of histone deacetylase-mediated diseases, such as cell proliferative diseases, inflammatory diseases, autosomal dominant diseases, genetic metabolic diseases, autoimmune diseases, acute/chronic neurological disease, hypertrophy, heart failure, ocular diseases, or neurodegenerative diseases.

  本发明涉及具有组蛋白去乙酰化酶（HDAC）抑制活性的新型杂环烷基衍生物，其光学异构体或其药学上可接受的盐，以及其用于制备药物、含有该药物的药物组合物、使用该组合物治疗疾病的方法，以及制备新型杂环烷基衍生物的方法。根据本发明的新型杂环烷基衍生物是选择性组蛋白去乙酰化酶（HDAC）抑制剂，可有效用于治疗组蛋白去乙酰化酶介导的疾病，如细胞增殖性疾病、炎症性疾病、常染色体显性疾病、遗传代谢性疾病、自身免疫性疾病、急性/慢性神经疾病、肥大、心力衰竭、眼部疾病或神经退行性疾病。
• [EN] ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES<br/>[FR] HYDROXAMATES CONNECTES A L'ACYLUREE ET A LA SULFONYLUREE
  申请人：S BIO PTE LTD

  公开号：WO2005040101A1

  公开（公告）日：2005-05-06

  The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to acylurea/sulfonylurea containing compounds and methods for their preparation. These compounds may be useful as medicaments for the treatment of proliferative disorders as well as other diseases involving, relating to or associated with enzymes having histone deacetylase activities.

  本发明涉及羟肟酸酯化合物，这些化合物是组蛋白去乙酰化酶的抑制剂。更具体地，本发明涉及含有酰脲/磺酰脲的化合物及其制备方法。这些化合物可能作为治疗增殖性疾病以及涉及、与组蛋白去乙酰化酶活性有关的其他疾病的药物而有用。